Oral Administration to Nursing Women of Lactobacillus fermentum CECT5716 Prevents Lactational Mastitis Development: A Randomized Controlled Trial

Autor: José A. Hurtado, Jose A. Maldonado-Lobón, M. Paz Díaz-Ropero, Katherine Flores-Rojas, José Uberos, José L. Leante, Laura Affumicato, María Luz Couce, José M. Garrido, Mónica Olivares, Juristo Fonollá, null the PROLAC Group
Přispěvatelé: [Hurtado, Jose A.] CHU, Dept Neonatol, Hosp Materno Infantil, Granada, Spain, [Maldonado-Lobon, Jose A.] Biosearch Life, Res Dept, Camino Purchil 66, Granada 18004, Spain, [Paz Diaz-Ropero, M.] Biosearch Life, Res Dept, Camino Purchil 66, Granada 18004, Spain, [Olivares, Monica] Biosearch Life, Res Dept, Camino Purchil 66, Granada 18004, Spain, [Fonolla, Juristo] Biosearch Life, Res Dept, Camino Purchil 66, Granada 18004, Spain, [Flores-Rojas, Katherine] Hosp Reina Sofia, Dept Metab & Pediat Res, Cordoba, Spain, [Uberos, Jose] Univ Granada, Sch Med, Dept Pediat, Granada, Spain, [Leante, Jose L.] Hosp GU Santa Lucia, Dept Neonatol, Murcia, Spain, [Affumicato, Laura] Hosp RU, Dept Neonatol, Malaga, Spain, [Luz Couce, Maria] Hosp CHU, Dept Neonatol, La Coruna, Spain, [Garrido, Jose M.] Hosp Univ Salamanca, Dept Pediat, Salamanca, Spain, Andalusian Government, European Regional Development Fund under Andalusia's Global Innovation-Technology-Enterprise Grant
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: Breastfeeding Medicine
ISSN: 1556-8342
1556-8253
Popis: Objective: The objective of this study is to evaluate the preventive effect of oral administration of Lactobacillus fermentum CECT5716 on mastitis incidence in lactating women. Methods: A randomized double-blinded controlled trial that included 625 women was conducted. Women who received preventive dose of antibiotic in the context of delivery were recruited 1–6 days after childbirth and randomly assigned to a group. Probiotic group received 1 capsule/day containing L. fermentum 3 × 109 CFU, control group received 1 placebo capsule/day containing maltodextrin. The intervention period was 16 weeks. The primary outcome of the study was the incidence of clinical mastitis defined as at least two out of the three breast symptoms (pain, redness, and lump) and at least one of fever or flu-like symptoms (shivering, hot sweats, or aches). Results: Two hundred ninety-one women completed 16 weeks of treatment. Sixteen women in the probiotic group developed mastitis versus 30 women in the control group (odds ratio = 0.531; p = 0.058). Incidence rate of mastitis in the probiotic group was significantly lower than that in the control group (IR = 0.130 in the probiotic group versus IR = 0.263 in the control group; p = 0.021). Therefore, the oral administration of L. fermentum CECT5716 during lactation decreased by 51% the incidence rate of clinical mastitis. Staphylococcus spp. load at the end of intervention was significantly lower in breast milk of women in the probiotic group than in breast milk of women in the control group (p = 0.025). Conclusion: Consumption of the probiotic strain L. fermentum CECT5716 might be used during breastfeeding as an efficient strategy to prevent development of lactational mastitis in women. Trial registration: NCT02203877.
Databáze: OpenAIRE